News Details

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 29, 2020 5:00 PM

CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its BTK inhibitor BRUKINSA™ (zanubrutinib) and its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and three posters at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-31, 2020.

Oral Presentation:

Title:

ASPEN: Results of a Phase III Randomized Trial of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)
 
Abstract #:8007

Session Title:
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Lead Author:

Constantine S. Tam, MBBS, M.D., St. Vincent’s Hospital, Australia
  

Poster Presentations:

Title:
 
Three-Year Follow-up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single-Agent Zanubrutinib
 
Abstract #:8051

Poster #: 384

Session Title:
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Lead Author:
Constantine S. Tam, MBBS, M.D., St. Vincent’s Hospital, Australia

  


Title:

Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC)
 
Abstract #:9554

Poster #: 320

Session Title:

Lung Cancer—Non-Small Cell Metastatic Poster Session

Lead Author:

Jie Wang, M.D., Cancer Hospital Chinese Academy of Medical Sciences, China

  


Title:

Association Between Immune and Tumor Gene Signatures with Response or Resistance to Tislelizumab Monotherapy or in Combination with Chemotherapy in Gastroesophageal Adenocarcinoma

Abstract #:3115

Poster #: 179

Session Title:

Developmental Therapeutics—Immunotherapy Poster Session

Lead Author
Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China

  

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene Investor Contact BeiGene Media Contact
Craig West
+1 857-302-5189
ir@beigene.com
Liza Heapes
+1 857-302-5663
media@beigene.com

BEI_ONC_4C_FlatLogo_Horizontal.jpg

Source: BeiGene, LTD.